BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22860709)

  • 1. S-1 for the treatment of gastrointestinal cancer.
    Satoh T; Sakata Y
    Expert Opin Pharmacother; 2012 Sep; 13(13):1943-59. PubMed ID: 22860709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of gastric cancer in Asia: the missing link.
    Nishida T
    Lancet Oncol; 2009 Nov; 10(11):1027-8. PubMed ID: 19880057
    [No Abstract]   [Full Text] [Related]  

  • 4. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
    Tokunaga Y; Sasaki H; Matsueda S
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [S-1 for gastric cancer-S-1 monotherapy and its progress].
    Shitara K; Sakata Y; Kudou T; Munakata M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of S-1 in colorectal cancer.
    Miyamoto Y; Sakamoto Y; Yoshida N; Baba H
    Expert Opin Pharmacother; 2014 Aug; 15(12):1761-70. PubMed ID: 25032886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations.
    Sanford M
    Drugs; 2013 Jun; 73(8):845-55. PubMed ID: 23719766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
    Blum M; Suzuki A; Ajani JA
    Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
    Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
    Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
    Yasui H; Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
    Jpn J Clin Oncol; 2009 May; 39(5):315-20. PubMed ID: 19403734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Schöffski P
    Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
    Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
    Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
    Ajani JA
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():117-20. PubMed ID: 16897985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [S-1 as a single agent for colorectal cancer].
    Eguchi T; Shirao K
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():121-4. PubMed ID: 16897986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].
    Sunaga T; Suzuki S; Harada N; Tanaka S; Hayashi T; Suzuki M
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):589-93. PubMed ID: 19381029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Latest progress on chemotherapy for advanced gastric cancer].
    Tahara M; Ohtsu A
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2048-58. PubMed ID: 11103236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
    Sasaki T; Koizumi W; Higuchi K; Ishido K; Ae T; Nakatani K; Katada C; Tanabe S; Saigenji K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):988-92. PubMed ID: 17637532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.